UNSPSC 51281505: Protionamide

This classification denotes an antitubercular agent with the molecular formula C9H12N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76YOO33643, chemically known as 4-pyridinecarbothioamide, 2-propyl- (9ci) but generally known as protionamide, which bears US NIH Compound Identifier 666418. European Medicines Agency schedules Protionamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10141MIG.

UNSPSC 51281505 Protionamide is a Commodity code that in recent state and local procurement activity covers purchase of pharmaceutical products and medical supplies, though the code itself—which nominally names a specific tuberculosis drug—does not align closely with the broader health and pharmaceutical procurement actually being tagged under it. Recent solicitations show state and local governments buying naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles, medical and first aid supplies for emergency response, and seeking vendor capacity for direct-to-manufacturer prescription programs. The issuing bodies span county health departments, state health commissions, municipal fire departments, and multistate cooperative purchasing alliances. Seminole County, Florida; the City of Tampa, Florida; the Texas Health and Human Services Commission; and the Minnesota Department of Administration (administering MMCAP on behalf of multiple state and local members including Oregon) are active recent buyers.

Activity concentrates in Florida and the Upper Midwest, with Texas and multistate cooperative purchasing extending reach. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB 60459723LAS, response deadline Jul 26, 2026); the City of Tampa's ITB for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000 and SLBE set-aside designation (Bid 26-P-00145, response deadline Mar 13, 2026); the Minnesota Department of Administration's RFP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through MMCAP (S1070000015802, response deadline Mar 26, 2026); and the Texas Health and Human Services Commission's RFI regarding direct-to-manufacturer prescription programs (HHS0017013, posted Apr 3, 2026). The mismatch between the code's nominal drug name and the diverse pharmaceutical and medical supply procurement actually solicited suggests this code may be misapplied in state and local tagging systems; a business development professional should verify current categorization with issuing bodies before investing in pursuit strategy.